Anthem biosciences Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with stock exchanges on April 06, 2026, ensuring adherence to regulatory requirements for securities dematerialization.

Regulatory Compliance Filing

The certificate was filed pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide periodic confirmations regarding the dematerialization and rematerialization of securities during specified quarters.

Certificate Issuance and Verification

Kfin Technologies Limited, serving as the Registrar to an Issue and Share Transfer Agent for Anthem Biosciences Limited, issued the compliance certificate on April 02, 2026. The certificate was signed by Ganesh Chandra Patro, Deputy Vice President at Kfin Technologies Limited.

The registrar confirmed that all details of securities dematerialized and rematerialized during the quarter ended March 31, 2026 have been furnished to stock exchanges where the company's shares are listed. This certification ensures transparency in the company's securities handling processes.

Depository Communications

The compliance certificate was submitted to both major depositories in India:

• National Securities Depository Limited (NSDL) - Located at Trade World, Kamala Mills Compound, Lower Parel, Mumbai
• Central Depository Services (India) Limited (CDSL) - Located at Marathon Futurex, Lower Parel (East), Mumbai

Both communications carried identical certifications confirming compliance with SEBI regulations for the specified quarter.

Company Secretary Confirmation

Divya Prasad, Company Secretary & Compliance Officer (Membership No: A41438), digitally signed the submission on April 06, 2026. The filing was made on behalf of Anthem Biosciences Limited, formerly known as Anthem Biosciences Private Limited.

The company maintains its registered operations at Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bengaluru. This quarterly filing demonstrates the company's commitment to maintaining regulatory compliance and transparent reporting practices in accordance with SEBI guidelines.

Anthem biosciences Limited has announced the resignation of its General Counsel, Mr. K. Ramakrishnan, who will step down from his position effective March 31, 2026. The resignation was formally submitted on March 13, 2026, marking the end of a nearly two-decade association with the pharmaceutical company.

Senior Management Departure

Mr. Ramakrishnan has been with Anthem Biosciences since February 17, 2007, serving in various capacities before being appointed as General Counsel. His role was elevated to Senior Management Personnel status pursuant to Regulation 16 of SEBI LODR Regulations during the Board Meeting held on November 5, 2024.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and National Stock Exchange of India Limited, with the disclosure also made available on the company's official website.

Company Secretary and Compliance Officer Divya Prasad signed the regulatory filing, ensuring compliance with the Master Circular SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Transition Details

In his resignation letter addressed to Managing Director Ajay Bhardwaj, Mr. Ramakrishnan expressed gratitude for the opportunities provided during his tenure. He cited his superannuation and the company's recent listing as factors influencing his decision to step down from the role.

Upon his cessation from the General Counsel position, Mr. Ramakrishnan will also cease to be classified as a member of the Senior Management Personnel of the company. The transition is scheduled to be completed by the close of business on March 31, 2026.